Production (Stage)
Claritas Pharmaceuticals, Inc.
CLAZF
$0.00
$0.000.00%
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -37.47% | 49.18% | -55.59% | -27.65% | -27.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.47% | 49.18% | -71.35% | -471.64% | -62.24% |
| Operating Income | 37.47% | -49.18% | 71.35% | 471.64% | 62.24% |
| Income Before Tax | 212.07% | -64.80% | -119.93% | 92.96% | 112.89% |
| Income Tax Expenses | -- | -- | -4,227.27% | 900.00% | -- |
| Earnings from Continuing Operations | 212.07% | -64.80% | -116.50% | 92.29% | 105.94% |
| Earnings from Discontinued Operations | -- | 91.39% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 143.83% | 77.57% | -116.50% | 92.29% | 57.68% |
| EBIT | 37.47% | -49.18% | 71.35% | 471.64% | 62.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 133.55% | 82.36% | -115.63% | 92.47% | 60.93% |
| Normalized Basic EPS | 146.15% | -29.67% | -110.33% | 71.15% | 103.29% |
| EPS Diluted | 133.55% | 82.36% | -115.63% | 92.47% | 60.93% |
| Normalized Diluted EPS | 146.15% | -29.67% | -110.33% | 71.15% | 103.29% |
| Average Basic Shares Outstanding | 30.75% | 27.15% | 5.60% | 2.29% | 8.03% |
| Average Diluted Shares Outstanding | 30.75% | 27.15% | 5.60% | 2.29% | 8.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |